Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

EARNINGS AND TRADING: Michelmersh continues with positive order intake

16th May 2024 14:32

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

----------

Guild Esports PLC - London-based esports business - Enters into fighting game series, Tekken. Signs Awais Liaqat as its first professional Tekken player. "Awais, who has signed a 12-month contract with Guild, is a seasoned Tekken professional and the first esports player to represent Pakistan at an international level," it says. Chief Executive Jasmine Skee says: "We have been waiting for the right time to enter Tekken, and with the upcoming Esports World Cup and the launch of Tekken 8, now is the perfect opportunity. It is testament to our esports prestige that we have been able to attract a player of Awais' calibre to Guild, and we look forward to seeing him compete in a Guild jersey."

----------

Diaceutics PLC - Belfast-based provider of diagnostic commercialisation services to pharmaceutical and biotechnology companies - Increases the number of enterprise-wide engagements it has with "top 20 global pharma customers" to six engagements from four, across 29 separate therapeutic brands. Enterprise-wide engagements currently represent annual recurring revenue of GBP9.0 million, GBP2.5 million of which relates to the two additional engagements. CEO Ryan Keeling comments: "The strength of our growing pipeline of new enterprise-level contracts highlights the progress we are making in becoming the primary commercialisation partner for pharma and biotech companies launching new precision medicines, validating the accelerated investment in our platform technology. These new engagements represent a significant step forward towards our core mission of getting every eligible patient the right test and the right therapy to positively impact their disease outcome."

----------

Michelmersh Brick Holdings PLC - Haywards Heath, West Sussex-based brick maker - Says it has continued to experience positive momentum in order intake. Explains that momentum reflects "the benefits of our product portfolio's broad reach and the strong customer loyalty and distributor relationships we have across our end markets". Says it remains mindful of the higher interest rate environment and its impact on demand across the wider construction industry. Looking ahead, expects to deliver full year trade in line with full-year expectations.

----------

Ilika PLC - Romsey, England-based solid-state battery technology company - Trading for year ended April 30 has been in line with management expectations. Expects revenue to be about GBP2.1 million, up from GBP700,000 a year earlier. Loss before interest, tax, depreciation and amortisation comes in at GBP4.5 million, narrowed from GBP7.0 million.

----------

Anglo Asian Mining PLC - Azerbaijan-focused gold, silver and copper producer - Revenue in 2023 fell to USD45.9 million from USD84.7 million, due to lower production. Notes pretax loss USD32.0 million from a profit of USD7.5 million. Operating loss of USD24.8 million, versus a profit of USD9.3 million. "Despite the adversity, good progress was achieved in 2023," the company says. "Anglo Asian remains confident in delivering its medium-term growth strategy to become a mid-tier copper-focused miner by 2028."

----------

Water Intelligence PLC - London-based leak detection services company - Revenue increases by 6% to USD20.5 million in quarter ended March 31 from USD19.4 million a year earlier. Pretax profit climbs 14% to USD2.0 million from USD1.8 million. Ebitda rises by 9% to USD3.5 million from USD3.2 million.

----------

Arecor Therapeutics PLC - West Sussex, England-based biopharmaceutical firm - Revenue in 2023 comes in at GBP5.7 million from GBP3.7 million a year earlier. Pretax loss narrows to GBP8.9 million from GBP10.4 million. CEO Sarah Howell says: "I believe the group is in a strong position and we are poised to deliver against a number of key milestones in 2024, in particular, completion of the Phase I trial of AT278 with results expected in H1."

----------

By Sophie Rose, Alliance News senior reporter

Comments and questions to [email protected]

Copyright 2024 Alliance News Ltd. All Rights Reserved.

FTSE 100 Latest
Value8,084.61
Change-20.71